Developer docs
API playgroundTry for free, no card

Search company profiles

BIOIO

Full company profile

uuid0008yqw

Namestring
BIOIO
Legal namestring
BIOIO, Inc.
Websiteurl
bioio.tech
Company typeenum
Private
Founded yearint
2019
Descriptiontext

BIOIO, Inc. is a St. Louis-based longevity biotechnology company founded in 2019 that develops gerotherapies — drugs targeting core molecular mechanisms of aging — through its proprietary MOAT (Mechanism of Action Technologies) platform. MOAT is a mechanism-of-action-driven clinical indication prediction engine that combines experimental multi-omics with cell fitness-based, unbiased genome-wide screening, positioning it as a higher signal-to-noise approach to elucidating how small molecules work. MOAT 2.0, the second-generation platform, adds AI-generated virtual genomic screening and an in silico Gene2Drug module that has been validated in models of rheumatoid arthritis.

BIOIO's pipeline comprises two lead drug candidates: BIOIO-1001, a first-in-class insulin sensitizer that modulates Sirtuin 3 (Sirt3) via an NAD+-dependent pathway, inducing fatty acid oxidation without engaging PPARs and thereby bypassing limitations of fibrates, glitazars, and thiazolidinediones for type 2 diabetes; and BIOIO-2001, which targets sphingolipid biosynthesis (the SPT enzyme) and has been linked to diabetic neuropathy through a 2025 collaboration with University Hospital of Zurich. Both compounds are positioned as bona fide gerotherapies impinging on multiple hallmarks of aging, enabling a "pipeline-in-a-pill" strategy of multi-indication application per asset.

The company's commercial model is pre-revenue and built around licensing, partnerships, and grant funding rather than product sales. Strategic relationships include a 2020 oncology co-development partnership with SPARC (Sun Pharma), a 2022 LabDAO partnership to virtualize drug discovery, ongoing research collaborations with Washington University in St. Louis, and IP-NFT-structured funding from VitaDAO for BIOIO-2001. The company is led by founders Tim Peterson, PhD (CEO; MIT/Harvard HHMI-trained, former WashU Assistant Professor) and Joppe Nieuwenhuis, PhD (COO; Netherlands Cancer Institute-trained, ex-Rejuveron and Batavia Biosciences). Cumulative dilutive and non-dilutive funding is approximately $20M, anchored by NIH STTR grants, longevity-focused VCs (Lifespan Vision Ventures, quadraScope), and the Missouri Technology Corporation, which has backed the company in both January 2024 ($2.2M) and January 2026 ($5.8M) IDEA FUND cycles.

Short descriptiontext

BIOIO is a St. Louis-based longevity biotechnology company using its MOAT mechanism-of-action platform to identify drug candidates targeting aging pathways. Its pipeline includes BIOIO-1001, a first-in-class insulin sensitizer targeting Sirt3, and BIOIO-2001, targeting sphingolipid biosynthesis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, gerotherapy development, mechanism of action, longevity biotechnology, metabolic disease therapeutics
Industry2 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Discovery & Development
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development & Licensing
TypeLicensing Royalties
Description

BIOIO develops proprietary drug candidates (BIOIO-1001, BIOIO-2001) through its MOAT platform and plans to commercialize through licensing deals with pharmaceutical partners or through continued development toward clinical trials.

bioio.tech
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BIOIO is a longevity biotechnology company that develops proprietary drug candidates (gerotherapies) for cancer, metabolic disease, and aging-related conditions using its MOAT (Mechanism of Action Technologies) platform. The company combines experimental multi-omics approaches with AI-driven computational analysis to predict drug mechanisms and identify clinical indications, advancing first-in-class candidates such as BIOIO-1001 (an insulin sensitizer targeting Sirt3) and BIOIO-2001 (a sphingolipid biosynthesis inhibitor). BIOIO plans to commercialize its assets through licensing deals and strategic partnerships with pharmaceutical and biotech companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Insulin sensitization through NAD+-dependent Sirt3 modulation without PPAR dependency
+1 more record
Product overview1 text field

BIOIO is a longevity biotechnology company developing gerotherapies that target aging at its molecular core to extend health-span and longevity. The company's platform consists of the MOAT (Mechanism of Action Technologies) platform, which combines experimental multi-omics approaches with computational AI-driven analysis to predict clinical indications and identify drug mechanisms. MOAT 2.0 represents the second generation capable of virtual genomic screening. The pipeline includes two drug candidates: BIOIO-1001, a first-in-class insulin sensitizer targeting Sirtuin 3 for metabolic disease treatment, and BIOIO-2001, targeting sphingolipid biosynthesis for diabetic neuropathy. Both compounds act on lipid metabolism and impinge on multiple hallmarks of aging, creating a 'pipeline in a pill' approach where each asset can be applied to multiple clinical indications.

Product and service4 records
1MOAT Platform
CategoryDrug Discovery Technology
Description

A MoA-driven clinical indication prediction engine combining experimental multi-omics approaches with computational analysis and cell fitness-based unbiased genome-wide screening to identify small molecule mechanisms of action and predict clinical applications. Designed for pharmaceutical and biotech partners seeking novel drug candidates and MoA insights.

2MOAT 2.0
CategoryDrug Discovery Technology
Description

Second-generation platform that performs virtual genomic screens using AI-generated predictions to identify mechanism of action and clinical indications, significantly reducing time and cost compared to experimental-only approaches. Validated through the Gene2Drug module for chemical mimic identification.

3BIOIO-1001
CategoryDrug Candidate / Therapeutic Compound
Description

A first-in-class insulin sensitizer that targets Sirtuin 3 (Sirt3) via NAD+-dependent pathway modulation, inducing fatty acid oxidation without relying on PPARs. Developed for the treatment of type 2 diabetes mellitus by addressing insulin resistance at its root cause.

4BIOIO-2001
CategoryDrug Candidate / Therapeutic Compound
Description

A drug candidate targeting the sphingolipid biosynthesis pathway, addressing lipid metabolism and multiple hallmarks of aging. Funded by VitaDAO via Molecule's IP-NFT framework. Indicated for diabetic neuropathy and related metabolic conditions.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-10
Description

Partnership with Sun Pharma's SPARC initiative to use BIOIO's MOAT platform for oncology drug development, announced February 2020.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing research collaboration with WashU scientists including Yousef Abu Amer (arthritis research), Brian Finck and Kyle McCommis (BIOIO-1001 manuscript), and Gabriel Mbalaviele (TMEM178/NLRP3 research). WashU is the academic home of multiple BIOIO team members.

3University Hospital of Zurich
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration in November 2025 where MOAT found that Very long-chain fatty acids drive 1-deoxySphingolipid toxicity, a driver of Diabetic Neuropathy targeted by BIOIO-2001.

bioio.tech
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company combining generative biology with longevity/aging-disease pipeline. Closest direct peer to BIOIO given shared platform-plus-therapeutics model and explicit focus on aging-related indications.

TypeDirect peer
Description

Platform biotech combining high-throughput biology with ML to discover new therapeutics at scale. Directly comparable to BIOIO's MOAT approach of using systematic experimental data plus computation to drive indication prediction.

TypeDirect peer
Description

Computational chemistry and predictive modeling platform used for drug discovery by pharma clients and internal programs. Comparable to BIOIO's MOAT 2.0 virtual screening and platform-licensing model.

TypeDirect peer
Description

ML-driven drug discovery company combining induced pluripotent stem cell biology with machine learning to identify targets and predict indications. Directly comparable platform-plus-therapeutics approach to BIOIO's MOAT.

TypeDirect peer
Description

AI-driven small molecule discovery platform that partners with pharma and develops internal pipeline. Comparable to BIOIO's MOAT 2.0 virtual screening and pharma-licensing go-to-market.

TypeBroad incumbent
Description

Well-capitalized longevity biotech pursuing cellular rejuvenation programming. Comparable thematic adjacency to BIOIO's gerotherapy framing, but a much larger and broader incumbent in the same longevity space.

TypeEmerging player
Description

Early-stage longevity biotech applying epigenetic reprogramming to aged cell types. Comparable as a peer emerging-player in the longevity/gerotherapy category where BIOIO also competes for talent and capital.

TypeEmerging player
Description

Longevity therapeutics company developing drugs to extend dog healthspan, with FDA engagement on aging as an indication. Useful peer for understanding regulatory framing of gerotherapy — overlapping theme but different species focus.

TypeBroad incumbent
Description

Alphabet-backed longevity R&D organization pursuing fundamental biology of aging and age-related disease. Broad incumbent in the same aging/gerotherapy thematic category as BIOIO.

TypeOthers
Description

Decentralized longevity research DAO that funded BIOIO-2001 via IP-NFT. Included as an ecosystem/funder peer rather than a competitor; reflects the alternative capital channel BIOIO accesses.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BIOIO

Drug Discovery & Developmentbioio.tech

BIOIO is a St. Louis-based longevity biotechnology company using its MOAT mechanism-of-action platform to identify drug candidates targeting aging pathways. Its pipeline includes BIOIO-1001, a first-in-class insulin sensitizer targeting Sirt3, and BIOIO-2001, targeting sphingolipid biosynthesis.

What BIOIO does

BIOIO, Inc. is a St. Louis-based longevity biotechnology company founded in 2019 that develops gerotherapies — drugs targeting core molecular mechanisms of aging — through its proprietary MOAT (Mechanism of Action Technologies) platform. MOAT is a mechanism-of-action-driven clinical indication prediction engine that combines experimental multi-omics with cell fitness-based, unbiased genome-wide screening, positioning it as a higher signal-to-noise approach to elucidating how small molecules work. MOAT 2.0, the second-generation platform, adds AI-generated virtual genomic screening and an in silico Gene2Drug module that has been validated in models of rheumatoid arthritis.

BIOIO's pipeline comprises two lead drug candidates: BIOIO-1001, a first-in-class insulin sensitizer that modulates Sirtuin 3 (Sirt3) via an NAD+-dependent pathway, inducing fatty acid oxidation without engaging PPARs and thereby bypassing limitations of fibrates, glitazars, and thiazolidinediones for type 2 diabetes; and BIOIO-2001, which targets sphingolipid biosynthesis (the SPT enzyme) and has been linked to diabetic neuropathy through a 2025 collaboration with University Hospital of Zurich. Both compounds are positioned as bona fide gerotherapies impinging on multiple hallmarks of aging, enabling a "pipeline-in-a-pill" strategy of multi-indication application per asset.

The company's commercial model is pre-revenue and built around licensing, partnerships, and grant funding rather than product sales. Strategic relationships include a 2020 oncology co-development partnership with SPARC (Sun Pharma), a 2022 LabDAO partnership to virtualize drug discovery, ongoing research collaborations with Washington University in St. Louis, and IP-NFT-structured funding from VitaDAO for BIOIO-2001. The company is led by founders Tim Peterson, PhD (CEO; MIT/Harvard HHMI-trained, former WashU Assistant Professor) and Joppe Nieuwenhuis, PhD (COO; Netherlands Cancer Institute-trained, ex-Rejuveron and Batavia Biosciences). Cumulative dilutive and non-dilutive funding is approximately $20M, anchored by NIH STTR grants, longevity-focused VCs (Lifespan Vision Ventures, quadraScope), and the Missouri Technology Corporation, which has backed the company in both January 2024 ($2.2M) and January 2026 ($5.8M) IDEA FUND cycles.

BIOIO firmographics

Firmographics
Name
BIOIO
Legal name
BIOIO, Inc.
Website
https://bioio.tech
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
BIOIO is a St. Louis-based longevity biotechnology company using its MOAT mechanism-of-action platform to identify drug candidates targeting aging pathways. Its pipeline includes BIOIO-1001, a first-in-class insulin sensitizer targeting Sirt3, and BIOIO-2001, targeting sphingolipid biosynthesis.
Ownership category
akta.pro rank

BIOIO industry classification

Industry
Product category
Drug Discovery & Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Drug discovery platform
  • Gerotherapy development
  • Mechanism of action
  • Longevity biotechnology
  • Metabolic disease therapeutics

Where BIOIO is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BIOIO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Development & Licensing: BIOIO develops proprietary drug candidates (BIOIO-1001, BIOIO-2001) through its MOAT platform and plans to commercialize through licensing deals with pharmaceutical partners or through continued development toward clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

BIOIO product offering

Product offering

Core offering

BIOIO is a longevity biotechnology company that develops proprietary drug candidates (gerotherapies) for cancer, metabolic disease, and aging-related conditions using its MOAT (Mechanism of Action Technologies) platform. The company combines experimental multi-omics approaches with AI-driven computational analysis to predict drug mechanisms and identify clinical indications, advancing first-in-class candidates such as BIOIO-1001 (an insulin sensitizer targeting Sirt3) and BIOIO-2001 (a sphingolipid biosynthesis inhibitor). BIOIO plans to commercialize its assets through licensing deals and strategic partnerships with pharmaceutical and biotech companies.

Product overview

BIOIO is a longevity biotechnology company developing gerotherapies that target aging at its molecular core to extend health-span and longevity. The company's platform consists of the MOAT (Mechanism of Action Technologies) platform, which combines experimental multi-omics approaches with computational AI-driven analysis to predict clinical indications and identify drug mechanisms. MOAT 2.0 represents the second generation capable of virtual genomic screening. The pipeline includes two drug candidates: BIOIO-1001, a first-in-class insulin sensitizer targeting Sirtuin 3 for metabolic disease treatment, and BIOIO-2001, targeting sphingolipid biosynthesis for diabetic neuropathy. Both compounds act on lipid metabolism and impinge on multiple hallmarks of aging, creating a 'pipeline in a pill' approach where each asset can be applied to multiple clinical indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • MOAT Platform A MoA-driven clinical indication prediction engine combining experimental multi-omics approaches with computational analysis and cell fitness-based unbiased genome-wide screening to identify small molecule mechanisms of action and predict clinical applications. Designed for pharmaceutical and biotech partners seeking novel drug candidates and MoA insights.
  • MOAT 2.0 Second-generation platform that performs virtual genomic screens using AI-generated predictions to identify mechanism of action and clinical indications, significantly reducing time and cost compared to experimental-only approaches. Validated through the Gene2Drug module for chemical mimic identification.
  • BIOIO-1001 A first-in-class insulin sensitizer that targets Sirtuin 3 (Sirt3) via NAD+-dependent pathway modulation, inducing fatty acid oxidation without relying on PPARs. Developed for the treatment of type 2 diabetes mellitus by addressing insulin resistance at its root cause.
  • BIOIO-2001 A drug candidate targeting the sphingolipid biosynthesis pathway, addressing lipid metabolism and multiple hallmarks of aging. Funded by VitaDAO via Molecule's IP-NFT framework. Indicated for diabetic neuropathy and related metabolic conditions.

Quantifiable outcome

  • Insulin sensitization through NAD+-dependent Sirt3 modulation without PPAR dependency
  • +1 more outcomes

Companies that use BIOIO

Customer profile

Segments2 records

Ideal customer profiles2 records

BIOIO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

BIOIO partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • SPARC (Sun Pharma)coreStrategic or Co-development Partner · 10 February 2020Partnership with Sun Pharma's SPARC initiative to use BIOIO's MOAT platform for oncology drug development, announced February 2020.
  • Washington University (WashU)coreStrategic or Co-development PartnerOngoing research collaboration with WashU scientists including Yousef Abu Amer (arthritis research), Brian Finck and Kyle McCommis (BIOIO-1001 manuscript), and Gabriel Mbalaviele (TMEM178/NLRP3 research). WashU is the academic home of multiple BIOIO team members.
  • University Hospital of ZurichminorStrategic or Co-development PartnerCollaboration in November 2025 where MOAT found that Very long-chain fatty acids drive 1-deoxySphingolipid toxicity, a driver of Diabetic Neuropathy targeted by BIOIO-2001.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

BIOIO competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery company combining generative biology with longevity/aging-disease pipeline. Closest direct peer to BIOIO given shared platform-plus-therapeutics model and explicit focus on aging-related indications.
  • Recursion Pharmaceuticals: Platform biotech combining high-throughput biology with ML to discover new therapeutics at scale. Directly comparable to BIOIO's MOAT approach of using systematic experimental data plus computation to drive indication prediction.
  • Schrödinger: Computational chemistry and predictive modeling platform used for drug discovery by pharma clients and internal programs. Comparable to BIOIO's MOAT 2.0 virtual screening and platform-licensing model.
  • Insitro: ML-driven drug discovery company combining induced pluripotent stem cell biology with machine learning to identify targets and predict indications. Directly comparable platform-plus-therapeutics approach to BIOIO's MOAT.
  • Atomwise: AI-driven small molecule discovery platform that partners with pharma and develops internal pipeline. Comparable to BIOIO's MOAT 2.0 virtual screening and pharma-licensing go-to-market.

Broad incumbents

  • Altos Labs: Well-capitalized longevity biotech pursuing cellular rejuvenation programming. Comparable thematic adjacency to BIOIO's gerotherapy framing, but a much larger and broader incumbent in the same longevity space.
  • Calico Life Sciences: Alphabet-backed longevity R&D organization pursuing fundamental biology of aging and age-related disease. Broad incumbent in the same aging/gerotherapy thematic category as BIOIO.

Emerging players

  • NewLimit: Early-stage longevity biotech applying epigenetic reprogramming to aged cell types. Comparable as a peer emerging-player in the longevity/gerotherapy category where BIOIO also competes for talent and capital.
  • Loyal for Dogs: Longevity therapeutics company developing drugs to extend dog healthspan, with FDA engagement on aging as an indication. Useful peer for understanding regulatory framing of gerotherapy — overlapping theme but different species focus.

Others

  • VitaDAO: Decentralized longevity research DAO that funded BIOIO-2001 via IP-NFT. Included as an ecosystem/funder peer rather than a competitor; reflects the alternative capital channel BIOIO accesses.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BIOIO social profiles

Digital presence

BIOIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BIOIO leadership team

Management profile

Number of profiles

Profiles2 records

BIOIO funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BIOIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOIO

What does BIOIO do?

BIOIO is a longevity biotechnology company that develops proprietary drug candidates (gerotherapies) for cancer, metabolic disease, and aging-related conditions using its MOAT (Mechanism of Action Technologies) platform. The company combines experimental multi-omics approaches with AI-driven computational analysis to predict drug mechanisms and identify clinical indications, advancing first-in-class candidates such as BIOIO-1001 (an insulin sensitizer targeting Sirt3) and BIOIO-2001 (a sphingolipid biosynthesis inhibitor). BIOIO plans to commercialize its assets through licensing deals and strategic partnerships with pharmaceutical and biotech companies.

Is BIOIO a public or private company?

BIOIO is a private company. It is classified as venture growth investor backed and is currently operating.

When was BIOIO founded?

BIOIO was founded in 2019. It employs 1 to 10 people.

Where is BIOIO based?

BIOIO is headquartered in St Louis, United States, in the North America region.

How does BIOIO make money?

One revenue line is on record: drug Development & Licensing.

Who are BIOIO's main competitors?

Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Insitro and Atomwise. Broad incumbents are Altos Labs and Calico Life Sciences. Emerging players are NewLimit and Loyal for Dogs. VitaDAO is listed as an others.

Does BIOIO have an API?

No public API is recorded for BIOIO.

What industry is BIOIO in?

BIOIO's product category is Drug Discovery & Development. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales